Tuberculosis (TB) is on the rise, with the World Health Organization (WHO) calling it a public health crisis and increasingly resistant to antibiotics. Researchers from the University of Sydney have found that three experimental antibiotic compounds, ecumicin, ilamycins, and cyclomarins, can disrupt the protein recycling system of Mycobacterium tuberculosis, the bacterium that causes TB. They found that each compound disrupts the system in a different way, causing widespread imbalances across the whole bacterium. The study suggests that these compounds could potentially be used as effective treatments against TB, which is currently claiming over a million lives a year.